The overall goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE)Administration Core is to stimulate research in lymphoma and to expedite the translation of discoveries intonew and better methods of prevention, detection, and treatment of lymphoma. The Administration Core hasserved well as the organizational hub of UI/MC SPORE during the initial funding period. During the next grantperiod it will continue to provide an organizational structure designed to efficiently coordinate the activities ofthe research projects, scientific cores, and developmental programs (Developmental Research Program,Career Development Program) of the UI/MC SPORE. It will also serve to enhance communication betweeninvestigators at Iowa and Mayo. The Administration Core will be responsible for coordinating the function ofthe SPORE committees including the Executive Committee and the External Advisory Committee. Dr. GeorgeWeiner will serve as Director of the Administration Core, and Dr. Thomas Witzig as Co-Director. Weiner andWitzig functioned well as a team during the initial funding period, and will continue to work collaboratively toprovide expertise in laboratory and clinical lymphoma research. They have extensive administrativeexperience and are well qualified to provide leadership and direction for the UI/MC SPORE. TheAdministration Core will support SPORE activities by: (1) providing leadership, organizational support, andfinancial management for UI/MC SPORE investigators; (2) coordinating monthly videoconferences andquarterly meetings of UI/MC SPORE investigators, and the ongoing scientific review of SPORE researchprojects and cores, and the visits of the external advisors; (3) providing the infrastructure for the selection andsupport of the best and most promising projects as outlined in SPORE guidelines; (4) providing for informationtransfer to the scientific community via professional and public means; (5) providing the structure for theestablishment and nurture of collaborations to facilitate and expand lymphoma research; (6) assuring inputfrom patient advocates and (7) fostering trainee development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097274-06
Application #
7254596
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-08-17
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$193,314
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598

Showing the most recent 10 out of 387 publications